University of Wollongong R&D Collaboration
Filed with ASX · · 4 pages · English
Earlier from Racura Oncology
- Race secures sixth US patent for Zantrene
- Race secures fifth US patent for Zantrene
- Preclinical & Clinical Programs Update
- Zantrene highly effective in Melanoma preclinical study
- First Patient Dosed in Phase 1b/2 AML Trial
Later from Racura Oncology
- Breakthrough Zantrene Heart Protection Discovery
- AGM Presentations
- Race Oncology Share Purchase Plan
- Race Oncology Investor Presentation - November 2021
- Race Oncology: Notification regarding unquoted securities - RAC
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology